Vaxil's focuses on the following therapeutic areas:

> Cancer:
development of ImMucin, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen (TAA). ImMucin has successfully completed a Phase I/II clinical trial in Multiple Myeloma patients and it is currently being evaluated in metastatic breast cancer patients in combination with hormonal therapy. Further clinical studies are planned.

> Tuberculosis: development of MTbuVax, an improved multi-antigenic and multi-epitope subunit vaccine against the intracellular pathogenic bactria mycobacterium Tuberculosis (Mtb). MTbuVax is aimed to boost the immunity in BCG immunized patients and/or to be used as a theraputic vaccine in TB patients, most probably with other anti-TB drugs. MTbuVax is currently at preclinical stage of development. 


Vaxil was founded in late 2006 by an experienced management team supported by leading scientists and clinicians. It is headquartered at the Weizmann Science Park, Nes –Ziona, Israel.

Vaxil BioTherapeutics Ltd. (TASE:VAXL), is a clinical stage company developing a new class of synthetic therapeutic and preventive vaccines with promiscuous antigen specific T and B-cell activation, based on its proprietary VaxHit technology.